We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+50.47%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$566M
AUM Growth
+$244M
Cap. Flow
+$79.7M
Cap. Flow %
14.07%
Top 10 Hldgs %
52.72%
Holding
83
New
26
Increased
22
Reduced
20
Closed
11

Top Buys

Rank Stock Value
1
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$10.7M
2
SNY icon
Sanofi
SNY
+$9.45M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$9.01M
4
PNTG icon
Pennant Group
PNTG
+$8.5M
5
MDCO
Medicines Co
MDCO
+$7.63M

Top Sells

Rank Stock Value
1
AMRN
Amarin Corp
AMRN
+$7.86M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$7.4M
3
ZGNX
Zogenix, Inc.
ZGNX
+$6.78M
4
DXCM icon
DexCom
DXCM
+$6.17M
5
ABMD
Abiomed Inc
ABMD
+$5.33M

Sector Composition

Rank Sector Weight
1 Healthcare 82.4%
2 Miscellaneous 13.14%
3 Real Estate 1.69%
4 Communication Services 1.29%
5 Industrials 0.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARGX icon
26
argenx
ARGX
$64B
$5.97M 1.05%
37,204
+1,200
+3% +$162K
ILMN icon
27
Illumina
ILMN
$32.6B
$5.89M 1.04%
18,247
-9,252
-34% -$2.8M
OXFD
28
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$5.81M 1.03%
349,823
+93,823
+37% +$1.52M
RCM
29
DELISTED
R1 RCM Inc. Common Stock
RCM
$5.41M 0.96%
416,726
-309,246
-43% -$3.53M
NTRA icon
30
Natera
NTRA
$47B
$5.29M 0.93%
+157,081
New +$5.79M
KDMN
31
DELISTED
Kadmon Holdings, Inc.
KDMN
$5.17M 0.91%
+1,141,939
New +$4.18M
GH icon
32
Guardant Health
GH
$21.7B
$5.06M 0.89%
+64,720
New +$4.66M
QGEN icon
33
Qiagen
QGEN
$8.9B
$4.63M 0.82%
+129,199
New +$4.8M
EHTH icon
34
eHealth
EHTH
$38.4M
$3.04M 0.54%
31,653
-11,000
-26% -$854K
OHI icon
35
Omega Healthcare
OHI
$13.9B
$3.03M 0.53%
71,500
-35,000
-33% -$1.48M
ELV icon
36
Elevance Health
ELV
$85.5B
$3.02M 0.53%
+10,000
New +$2.75M
AGRX
37
DELISTED
Agile Therapeutics
AGRX
$2.84M 0.5%
568
+113
+25% +$395K
XENE icon
38
Xenon Pharmaceuticals
XENE
$5.81B
$2.83M 0.5%
215,609
– –
LTC
39
LTC Properties
LTC
$2.19B
$2.66M 0.47%
59,327
-10,000
-14% -$480K
DXCM icon
40
DexCom
DXCM
$34.3B
$2.64M 0.47%
48,200
-130,000
-73% -$6.17M
CNC icon
41
Centene
CNC
$32B
$2.51M 0.44%
+40,000
New +$2.17M
IGMS
42
DELISTED
IGM Biosciences
IGMS
$2.47M 0.44%
+64,600
New +$1.62M
AFMD
43
DELISTED
Affimed
AFMD
$2.35M 0.42%
85,777
+53,560
+166% +$1.43M
COLL icon
44
Collegium Pharmaceutical
COLL
$786M
$2.29M 0.4%
111,361
-48,934
-31% -$816K
CTRE icon
45
CareTrust REIT
CTRE
$9.22B
$2.24M 0.4%
107,464
-30,000
-22% -$656K
BDSI
46
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$2.12M 0.37%
335,485
-372,535
-53% -$2.19M
OTIC
47
DELISTED
Otonomy, Inc.
OTIC
$2.11M 0.37%
550,665
+174,323
+46% +$426K
AQST icon
48
Aquestive Therapeutics
AQST
$630M
$2.04M 0.36%
+350,000
New +$1.82M
HSKA
49
DELISTED
Heska Corp
HSKA
$1.99M 0.35%
20,771
-20,053
-49% -$1.74M
ALBO
50
DELISTED
Albireo Pharma Inc
ALBO
$1.98M 0.35%
78,029
+60,000
+333% +$1.2M
1
2
3 4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q4 2019 Portfolio in Review

As of Q4 2019, Eversept Partners held 83 positions worth $566M, up 76% from $322M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Eversept Partners deployed $79.7M of net new capital in Q4 2019, opening 26 new positions and adding to 22 existing holdings. Its largest new stake was ChemoCentryx, Inc.: 513,189 shares worth $20.3M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 90% a quarter earlier, followed by Miscellaneous and Real Estate.

On the sell side, the largest reduction was Amarin Corp, an estimated $7.86M trimmed.

  • Eversept Partners's largest Q4 2019 buy was ChemoCentryx, Inc.: 513,189 shares worth $20.3M.
  • Eversept Partners added most to BioCryst Pharmaceuticals in Q4 2019, an estimated $10.7M increase.
  • Eversept Partners's biggest Q4 2019 reduction was Amarin Corp, cutting an estimated $7.86M.
  • Eversept Partners fully exited Alnylam Pharmaceuticals in Q4 2019, selling an estimated $7.4M.
  • Eversept Partners's ten largest holdings make up 53% of its $566M portfolio in Q4 2019.
  • Eversept Partners opened 26 new positions and closed 11 in Q4 2019.
  • Eversept Partners's portfolio value rose 76% quarter-over-quarter to $566M.

Based on Eversept Partners's 13F filing for Q4 2019, filed 13 Feb 2020.